Currently conducting a Phase IIa dose-escalating trial with 12 ALS patients at the Hadassah Medical Center in Jerusalem, Israel, the company is scheduled to begin a Phase II multi-center ALS trial in the US following FDA approval.
BrainStorm CEO Alon Natanson said, "We chose PRC Clinical to manage our upcoming US-based trial based on their comprehensive range of support services, their experience with both orphan drug trials and neurological disease, specifically ALS, and their use of state-of-the-art monitoring and management technologies."
PRC Clinical offers a range of clinical management services such as protocol development, project management, and regional monitoring to clinical data management and clinical payment services to support Phase I-IV clinical studies.
Commenting on the agreement, PRC Clinical president and CEO Curtis Head said, "PRC Clinical is delighted to have been selected as the CRO for this trial and we are committed to providing BrainStorm’s clinical development program with the highest quality management and data."